# Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

> **NCT06132035** · PHASE1 · RECRUITING · sponsor: **Caregen Co. Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Age-related Wet Macular Degeneration

## Interventions

- **DRUG:** CG-P5 peptide
- **DRUG:** Placebo
- **DRUG:** Aflibercept Injection [Eylea]

## Key facts

- **NCT ID:** NCT06132035
- **Lead sponsor:** Caregen Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-22
- **Primary completion:** 2025-05
- **Final completion:** 2025-08
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132035, "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06132035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*